Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      APP Pharmaceuticals to Launch Drug Hotline


      APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., /quotes/comstock/15*!apcvz/quotes/nls/apcvz (APCVZ 0.04, 0.00, -2.63%) announced today that it will launch the APP Drug Hotline on Wednesday, November 10, 2010. The APP Drug Hotline has been established to assist healthcare professionals with critical drug shortage issues.

      Staffed by an experienced Customer Service team, the APP Drug Hotline is dedicated to responding to inquires from healthcare professionals seeking information on whether APP's product portfolio can augment the supply of specific drugs currently on the U.S. Food and Drug Administration (FDA) and American Society of Health-System Pharmacists (ASHP) drug shortage lists. APP Drug Hotline staff will provide callers with an enhanced customer service experience, which includes real-time information on APP's available supply of specific drugs currently on drug shortage, details on upcoming APP product releases, as well as help callers track their APP orders.

      "Throughout the years, APP Pharmaceuticals has demonstrated that it can meet the challenges of critical drug shortages, and we are acutely aware of the pressure that healthcare professionals are under when a needed drug is unavailable. We have worked collaboratively with the FDA to alleviate shortages for many products ranging from Acyclovir to Heparin and most recently propofol," said John Ducker, President and CEO, APP Pharmaceuticals. "Responsiveness is APP's commitment to healthcare professionals and we understand the importance of product supply meeting patient demand."

      Healthcare professionals looking to learn more about how APP can help with their drug shortage needs can reach the APP Drug Hotline at (888) 386-1300, option 6. The APP Drug Hotline is available Monday through Friday, between the hours of 7:00 a.m. and 6:00 p.m. (CST).

      Information on current inventory and product availability is also accessible on the company's Web site,, by clicking on Drug Shortage Solutions.

      About APP Pharmaceuticals, Inc.

      APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company's Web site at

      About Fresenius Kabi AG

      Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy "caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2009, Fresenius Kabi achieved sales of EUR 3,086 million and an operating profit of EUR 607 million. For more information visit the company's Web site at Fresenius Kabi AG is a 100% subsidiary of Fresenius SE.

      Forward-Looking Statement

      The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. Additional relevant information concerning risks are discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2009 and other documents the company has filed with the Securities and Exchange Commission.

      The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company's expectations.

      Nov 10, 2010


      Share this Article!

    Back to top^